Please wait while the formulary information is being retrieved.
ABACAVIR-LAMIVUDINE-ZIDOVUDINE (ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE)
- HIV infection
300 mg-150 mg-300 mg tablet
- 1 tablet by oral route 2 times per day
abacavir 300 mg-lamivudine 150 mg-zidovudine 300 mg tablet
- 1 tablet by oral route 2 times per day
HIV infection
- 1 tablet by oral route 2 times per day
- None
Contraindicated
- Adriamycin
- Adriamycin Pfs
- clozapine
- Clozaril
- Copegus
- Cytovene
- deferiprone
- Doxil
- doxorubicin
- doxorubicin HCl peg-liposomal
- Fazaclo
- Ferriprox
- ganciclovir sodium
- Lipodox
- Lipodox 50
- Moderiba
- Moderiba Dose Pack
- Rebetol
- Ribapak Dose Pack
- Ribasphere
- Ribatab Dose Pack
- ribavirin
- stavudine
- Versacloz
- Virazole
- Zerit
Severe
Moderate
- colchicine-probenecid
- Diskets
- Dolophine
- methadone
- Methadone Intensol
- Methadose
- probenecid
- Acute pancreatitis
- Chronic pancreatitis
- Disease of liver
- HLa-B 57:01 positive
- Lactating mother
- Lactic acidosis
- Pancreatitis
- Severe hepatic disease
Contraindicated
- Anemia
- Bone marrow depression
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Hepatomegaly
- Myopathy
- Myositis
- Neutropenic disorder
Severe
Moderate
- Coronary artery disease
- Disease of liver
- Hypertriglyceridemia
- Kidney disease with likely reduction in GFR
- Toxic amblyopia
ABACAVIR-LAMIVUDINE-ZIDOVUDINE (ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE)
- HIV infection
- Anemia
- Elevated serum lipase
- Headache disorder
- Leukopenia
- Neutropenic disorder
- Paresthesia
- Anorexia
- Cough
- Diarrhea
- Dream disorder
- Fatigue
- Fever
- Headache disorder
- Infection of ear
- Insomnia
- Lipodystrophy associated with HIV
- Malaise
- Myalgias
- Nausea
- Peripheral neuropathy
- Sleep disorder
- Sore throat
- Vomiting
More Frequent
Severe
Less Severe
- Acute abdominal pain
- Arthralgias
- Bronchitis
- Cough
- Drug fever
- Dyspnea
- Hypersensitivity drug reaction
- Myalgias
- Neutropenic disorder
- Pharyngitis
- Skin rash
- Thrombocytopenic disorder
- Abdominal pain with cramps
- Anorexia
- Arthralgias
- Chills
- Constipation
- Dizziness
- Dyspepsia
- Fatigue
- General weakness
- Hypertriglyceridemia
- Insomnia
- Macrocytosis
- Musculoskeletal pain
- Myalgias
- Nail discoloration
- Peripheral sensory neuropathy
- Rhinitis
- Symptoms of anxiety
- Upper respiratory infection
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Acute respiratory distress syndrome
- Anaphylaxis
- Anemia
- Angioedema
- Anorexia
- Aplastic anemia
- Cardiomyopathy
- CNS toxicity
- Edema
- Erythema multiforme
- Graves' disease
- Guillain-barre syndrome
- Hemolytic anemia
- Hepatitis
- Hepatomegaly
- Hypotension
- Increased alanine transaminase
- Increased aspartate transaminase
- Jaundice
- Lactic acidosis
- Lymphadenopathy
- Macular retinal edema
- Manic disorder
- Multiple organ failure
- Myopathy
- Myositis
- Pancreatitis
- Pancytopenia
- Paresthesia
- Pneumonia
- Polymyositis
- Pure red cell aplasia
- Renal failure
- Rhabdomyolysis
- Seizure disorder
- Splenomegaly
- Steatosis of liver
- Stevens-johnson syndrome
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
- Vasculitis
Less Severe
- Acute confusion
- Alopecia
- Amblyopia
- Cramps
- Depression
- Dizziness
- Drowsy
- Dyschromia
- Dysgeusia
- Dysphagia
- Dyspnea
- Flatulence
- Flu-like symptoms
- General weakness
- Gynecomastia
- Hearing loss
- Hyperbilirubinemia
- Hyperglycemia
- Hyperhidrosis
- Hyperpigmentation of oral mucosa
- Increased urinary frequency
- Lipodystrophy
- Lymphadenopathy
- Muscle weakness
- Paresthesia
- Photophobia
- Pruritus of skin
- Rhinitis
- Sinusitis
- Skin rash
- Stomatitis
- Symptoms of anxiety
- Syncope
- Tremor
- Urinary hesitancy
- Urticaria
- Vertigo
- Wheezing
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Abacavir_Lamivudine_Zidovudine
Fixed dose combination not intended for children with weight < 40 kg.
- 1 Day – 15 Years
- Fixed dose combination not intended for children with weight < 40 kg.
Abacavir
- Severity Level:
2
- Additional Notes: Art preg registry data show no increased risk for major birth defects
Lamivudine
- Severity Level:
2
- Additional Notes: No fda cat;art preg registry data show no increased risk for major birth defects
Zidovudine
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects.
Contraindicated
Abacavir
Cdc does not recommend breastfeeding in hiv-positive women
Avoid breastfeeding in hiv positive women per cdc
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Lamivudine
Cdc does not recommend breastfeeding in hiv-positive women
Avoid breastfeeding in hiv positive women per cdc
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Avoid breastfeeding in hiv positive women per cdc |
Zidovudine
Cdc does not recommend breastfeeding in hiv-positive women
Avoid breastfeeding in hiv positive women per cdc
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Cdc does not recommend breastfeeding in hiv-positive women |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- In some patients, the abacavir in this product has caused a serious (sometimes fatal) allergic reaction. Your doctor should order a blood test to measure your risk before you start this medication or take it again. If the blood test shows you are at greater risk, you should not take this medication and your doctor should discuss other treatment choices with you.<br /><br />Symptoms of an allergic reaction may include any of the following: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing, fever, extreme tiredness, nausea, vomiting, diarrhea, stomach pain, muscle aches, sore throat, mouth sores, or cough. Get medical help right away if you experience any of these symptoms. If you have stopped taking abacavir because of an allergic reaction, you must never take any form of abacavir again, or death could result.<br /><br />Tell all of your doctors and pharmacists if you have stopped taking abacavir due to an allergic reaction. Also, properly throw away any unused medications containing abacavir. Read the warning card provided with this medication for more details.<br /><br /> The zidovudine in this product can decrease bone marrow function, which may lead to low numbers of red and white blood cells. A low number of red blood cells can lead to anemia. A low number of white blood cells can decrease your body's ability to fight serious, life-threatening infections.<br /><br />These serious side effects occur more frequently in people with advanced HIV disease (AIDS). Get medical help right away if you develop any signs of anemia (such as unusual tiredness, fast breathing, pale skin, fast heartbeat) or signs of infection (such as fever, chills, cough, persistent sore throat). Your doctor will check your blood cell counts while you are taking this medication to decrease the risk of these side effects.<br /><br /> Zidovudine may also cause muscle problems. Get medical help right away if you develop signs of muscle problems (such as wasting or decrease in muscle size, weight loss, muscle weakness/pain/tenderness). Rarely, abacavir/lamivudine/zidovudine has caused severe (sometimes fatal) liver problems and a certain metabolic problem (lactic acidosis).<br /><br />Get medical help right away if you develop any of the following symptoms: nausea, vomiting, stomach/abdominal pain, unusual tiredness, dark urine, yellowing eyes/skin, deep/rapid breathing, or drowsiness. These serious side effects may occur more often in women and obese patients. If you have hepatitis B infection and HIV, you may have a serious worsening of hepatitis symptoms if you stop taking lamivudine.<br /><br />Talk with your doctor before stopping this medication. Your doctor will monitor liver tests for several months after you stop lamivudine. Get medical help right away if you develop symptoms of worsening liver problems.
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
| 0-9 | A-Z |
|---|---|
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool